Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease
Clicks: 215
ID: 116022
2005
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
215 views
50 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #39 of 85 articles by views in Annals of hematology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Several approved therapies for multicentric Castleman disease (MCD) cannot be uniformly applied due to intolerable side effects. There is also a high percentage of recurrence of this disease despite treatment. Rituximab may be effective in controlling MCD in a subset of patients. This paper includes a brief case report and an extensive review of previously published cases. We observed an aggravation of concomitant cutaneous Kaposi sarcoma, and hypothesize that rituximab could have exacerbated it.
| Reference Key |
casquero2005annalsuse
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Angela Casquero;Alicia Barroso;Manuel L. Fernández Guerrero;Miguel Górgolas;Angela Casquero;Alicia Barroso;Manuel L. Fernández Guerrero;Miguel Górgolas; |
| Journal | Annals of hematology |
| Year | 2005 |
| DOI |
doi:10.1007/s00277-005-0038-4
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.